CN102399197A - 2-(2-羟基-2-取代苯乙基硫基]-3h-嘧啶-4-酮类化合物及其合成方法与用途 - Google Patents
2-(2-羟基-2-取代苯乙基硫基]-3h-嘧啶-4-酮类化合物及其合成方法与用途 Download PDFInfo
- Publication number
- CN102399197A CN102399197A CN2011103588115A CN201110358811A CN102399197A CN 102399197 A CN102399197 A CN 102399197A CN 2011103588115 A CN2011103588115 A CN 2011103588115A CN 201110358811 A CN201110358811 A CN 201110358811A CN 102399197 A CN102399197 A CN 102399197A
- Authority
- CN
- China
- Prior art keywords
- hydroxyl
- pyrimidin
- compounds
- substituted
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000001308 synthesis method Methods 0.000 title abstract 2
- 239000003814 drug Substances 0.000 claims abstract description 21
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical group FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims abstract description 16
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims abstract description 16
- 239000011737 fluorine Chemical group 0.000 claims abstract description 16
- 229910052731 fluorine Inorganic materials 0.000 claims abstract description 16
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 15
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 14
- 238000002360 preparation method Methods 0.000 claims abstract description 11
- 239000001257 hydrogen Substances 0.000 claims abstract description 8
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 8
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract description 8
- GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical group [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 claims abstract description 7
- 208000005176 Hepatitis C Diseases 0.000 claims abstract description 4
- -1 cyclohexyl methyl-3H-pyrimidin-4-one Chemical compound 0.000 claims description 50
- UHOVQNZJYSORNB-UHFFFAOYSA-N monobenzene Natural products C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 45
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 24
- 125000001797 benzyl group Chemical class [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 22
- 239000005864 Sulphur Substances 0.000 claims description 19
- 238000006243 chemical reaction Methods 0.000 claims description 17
- 239000000243 solution Substances 0.000 claims description 10
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 8
- 239000002994 raw material Substances 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 5
- 239000011259 mixed solution Substances 0.000 claims description 3
- 230000035484 reaction time Effects 0.000 claims description 3
- 239000002552 dosage form Substances 0.000 claims 1
- 229940000406 drug candidate Drugs 0.000 claims 1
- 125000001997 phenyl group Chemical class [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 abstract description 21
- 229940079593 drug Drugs 0.000 abstract description 9
- 241000711549 Hepacivirus C Species 0.000 abstract description 3
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 20
- 239000007787 solid Substances 0.000 description 17
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 9
- 229960000329 ribavirin Drugs 0.000 description 9
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
- 238000010790 dilution Methods 0.000 description 8
- 239000012895 dilution Substances 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 239000002904 solvent Substances 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 241000700605 Viruses Species 0.000 description 7
- 150000001555 benzenes Chemical class 0.000 description 7
- 238000003756 stirring Methods 0.000 description 6
- 238000000034 method Methods 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 238000010025 steaming Methods 0.000 description 5
- 238000013019 agitation Methods 0.000 description 4
- 230000000840 anti-viral effect Effects 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical class OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- GHLWXBNVZBKUGW-UHFFFAOYSA-N diethyl propanedioate;potassium Chemical class [K].CCOC(=O)CC(=O)OCC GHLWXBNVZBKUGW-UHFFFAOYSA-N 0.000 description 3
- 235000019441 ethanol Nutrition 0.000 description 3
- 238000003810 ethyl acetate extraction Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 231100001274 therapeutic index Toxicity 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 102000006992 Interferon-alpha Human genes 0.000 description 2
- 108010047761 Interferon-alpha Proteins 0.000 description 2
- 230000001464 adherent effect Effects 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- LJOODBDWMQKMFB-UHFFFAOYSA-N cyclohexylacetic acid Chemical compound OC(=O)CC1CCCCC1 LJOODBDWMQKMFB-UHFFFAOYSA-N 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 125000005909 ethyl alcohol group Chemical group 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 208000019423 liver disease Diseases 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- 229960003424 phenylacetic acid Drugs 0.000 description 2
- 239000003279 phenylacetic acid Substances 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000006722 reduction reaction Methods 0.000 description 2
- 238000012827 research and development Methods 0.000 description 2
- 238000000967 suction filtration Methods 0.000 description 2
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- 230000029812 viral genome replication Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- LTMRRSWNXVJMBA-UHFFFAOYSA-L 2,2-diethylpropanedioate Chemical class CCC(CC)(C([O-])=O)C([O-])=O LTMRRSWNXVJMBA-UHFFFAOYSA-L 0.000 description 1
- HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- KWOLFJPFCHCOCG-UHFFFAOYSA-N Acetophenone Chemical class CC(=O)C1=CC=CC=C1 KWOLFJPFCHCOCG-UHFFFAOYSA-N 0.000 description 1
- XZQCXNJGKNXFHC-UHFFFAOYSA-N C1(CCCCC1)CC1=C(C(NC(=N1)C1C(C=CC=C1)(SCC)O)=O)C Chemical compound C1(CCCCC1)CC1=C(C(NC(=N1)C1C(C=CC=C1)(SCC)O)=O)C XZQCXNJGKNXFHC-UHFFFAOYSA-N 0.000 description 1
- DRSHXJFUUPIBHX-UHFFFAOYSA-N COc1ccc(cc1)N1N=CC2C=NC(Nc3cc(OC)c(OC)c(OCCCN4CCN(C)CC4)c3)=NC12 Chemical compound COc1ccc(cc1)N1N=CC2C=NC(Nc3cc(OC)c(OC)c(OCCCN4CCN(C)CC4)c3)=NC12 DRSHXJFUUPIBHX-UHFFFAOYSA-N 0.000 description 1
- 101100136092 Drosophila melanogaster peng gene Proteins 0.000 description 1
- 108010078851 HIV Reverse Transcriptase Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- WCBRNMQYDWBDAX-UHFFFAOYSA-N OC1(C(C=CC=C1)C1=NC(=C(C(N1)=O)C)CC1=CC=C(C=C1)OC)SCC Chemical compound OC1(C(C=CC=C1)C1=NC(=C(C(N1)=O)C)CC1=CC=C(C=C1)OC)SCC WCBRNMQYDWBDAX-UHFFFAOYSA-N 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 101800001554 RNA-directed RNA polymerase Proteins 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 241000726445 Viroids Species 0.000 description 1
- 229940124404 anti-hepatitis c virus drug Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 230000007541 cellular toxicity Effects 0.000 description 1
- 239000012295 chemical reaction liquid Substances 0.000 description 1
- 238000011097 chromatography purification Methods 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- VQAZCUCWHIIFGE-UHFFFAOYSA-N diethyl 2-ethylpropanedioate Chemical compound CCOC(=O)C(CC)C(=O)OCC VQAZCUCWHIIFGE-UHFFFAOYSA-N 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000004853 protein function Effects 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
技术领域
本发明属药物技术领域,具体涉及5-烷基-2-[2-羟基-2-取代苯乙基硫]-6-取代苄基/环己甲基-3H-嘧啶-4-酮类化合物,其合成方法及用途,也就是2-(2-羟基-2-取代苯乙基硫基)-3H-嘧啶-4-酮类化合物及其合成方法与用途。
背景技术
丙型肝炎是由丙型肝炎病毒(hepatitis C virus, HCV)引起的一种严重威胁人类健康的肝脏疾病。1989年,HCV首次被确认为非甲型、非乙型肝炎的主要病原体。据世界卫生组织(WHO)报道,2000年约占世界人口3%的人感染了此类病毒,并且每年约有300万~400万的新发病例,70%~90%形成慢性感染,30%发展为进展性肝病,包括肝硬化或肝癌。今年有报道指出,我国HCV感染者已超过4000万。由于病毒自身的生物学特征,目前临床上尚无有效疫苗和治疗药物。常用的HCV治疗方法包括干扰素α或聚乙二醇干扰素α联合利巴韦林治疗。但是仅有50%的患者可以获得持久病毒学应答,加之其昂贵的费用和毒副作用,使新型的、安全有效的抗HCV药物的研发迫在眉睫。近年来随着对HCV病毒各复制环节的研究及非结构蛋白功能的深入认识,针对减少HCV感染者体内病毒复制的特异性靶向抗病毒治疗(specifically targeted antiviral therapy for hepatitis C,STAT-C)药物研究取得了较大进展。目前已发现的靶点主要有内源性核糖体进入位点(IRES)、结构蛋白NS2、NS3、NS5AT和NS5B等。
发明内容
本发明旨在提供一种5-烷基-2-[2-羟基-2-取代苯乙基硫]-6-取代苄基/环己甲基-3H-嘧啶-4-酮类化合物。
本发明的目的还在于获得上述化合物的制备方法。
本发明的目的也在于获得上述化合物的用途。
本发明的技术方案如下:
1、本发明产品为一种5-烷基-2-[2-羟基-2-取代苯乙基硫]- 6-取代苄基/环己甲基-3H-嘧啶-4-酮类化合物,是一类具有如下通式的化合物:
发明产品5-烷基-2-[2-羟基-2-取代苯乙基硫]- 6-取代苄基/环己甲基-3H-嘧啶-4-酮类化合物的制备方法:以5-烷基-2-[(取代苯基)羰基甲硫基]-6-取代苄基/环己甲基-3H-嘧啶-4-酮类化合物为原料,在四氢呋喃和甲醇混合溶液中,冰浴条件下用NaBH4还原制备目标分子。其中,5-烷基-2-[(取代苯基)羰基甲硫基]-6-取代苄基/环己甲基-3H-嘧啶-4-酮类化合物与NaBH4的摩尔比为1:1.2,反应溶液为四氢呋喃和甲醇的混合溶液,反应温度为冰浴条件,反应时间为3~4小时。
对本发明产品的制备方法的进一步说明:按文献方法从环己基乙酸或取代苯乙酸(1)和烷基丙二酸二乙酯(2)出发,经缩合、关环、烷基化反应制得5-烷基-2-[(取代苯基) 羰基甲硫基]-6-取代苄基/环己甲基-3H-嘧啶-4-酮类化合物(5)(He Yan-Ping et. al. Bioorg. Med. Chem. Lett. 2011, 21: 694-697;Yao zhi-kun et. al. Monatsh für Chemie, 2008, 139:967-974. ),然后以四氢呋喃和甲醇为溶剂,在冰浴条件下用硼氢化钠(NaBH4)进行还原反应制备目标分子(6),其反应式如下所示:
其中:
(2)5-烷基-2-[(取代苯基)羰基甲硫基]-6-取代苄基/环己甲基-3H-嘧啶-4-酮类化合物与NaBH4的摩尔比为1:1.2,反应溶液为四氢呋喃和甲醇的混合溶液,反应温度为冰浴条件,反应时间为3~4小时。
(3)5-烷基-2-[2-羟基-2-取代苯基乙基硫]- 6-取代苄基/环己甲基-3H-嘧啶-4-酮类化合物(6)的优选操作步骤如下:
将26 mmol 的5-烷基-2-[(取代苯基) 羰基甲硫基]-6-取代苄基/环己甲基-3H-嘧啶-4-酮类化合物(5)置于带有磁力搅拌的干燥三颈瓶中,加入20 mL的四氢呋喃和甲醇的混合溶液,于冰浴条件,在搅拌下分批加入NaBH4 (31.2 mmol),冰浴下继续搅拌反应3-4小时,TLC跟踪原料点消失,滴加少量水猝灭反应,减压除去溶剂,加入20 mL水稀释,再加入6 M的盐酸调pH = 6,用乙酸乙酯萃取溶液,无水Na2SO4干燥,减压浓缩得固体粗品,经柱层析纯化得固体纯品6a-m,结构见表1。
3、5-烷基-2-[2-羟基-2-取代苯乙基硫]- 6-取代苄基/环己甲基-3H-嘧啶-4-酮类化合物的应用
本发明产品的用途是作为抗丙型肝炎病毒药物候选物。
发明的有益效果:本发明化合物合成便利,对HCV病毒具有明显的抑制作用,其治疗指数高于现临床药物干扰素α-1b (IFNα-1b)和利巴韦林(Ribavirin),因此可作为抗HCV药物候选物用途。
具体实施方式
通过下述实施例将有助于理解本发明,但不能限制本发明的范围。
实施例一 β-酮酸酯(3)的制备
将0.1 mol的取代丙二酸二乙酯(2)(甲基丙二酸二乙酯,乙基丙二酸二乙酯)置于150 mL无水乙醇中,加入0.1 mol的KOH的乙醇溶液,室温搅拌12小时,减压蒸去溶剂,用***或乙酸乙酯洗两次,再次减压蒸去溶剂,制得取代丙二酸二乙酯单钾盐,直接用于下步反应。
将0.1 mol的取代丙二酸二乙酯单钾盐置于150 mL无水乙腈中,依次加入0.18 mol的无水MgCl2, 0.15 mol Et3N,室温搅拌2个小时;将0.048 mol的取代苯乙酸/环己乙酸(1)置于100 mL的无水乙腈中,逐批加入0.05 mol的N,N-羰基二咪唑,反应一个小时,然后将反应混合液加入取代丙二酸二乙酯单钾盐、无水MgCl2和Et3N的混合液中,室温搅拌过夜,加热回流3-5小时,TLC追踪至反应完全;冷却反应液,用13%的盐酸调pH值为6左右,分层,取有机层减压蒸去溶剂,水层用乙酸乙酯萃取3次,合并有机层,依次用饱和NaHCO3溶液、饱和NaCl溶液洗涤,无水Na2SO4干燥过夜,减压蒸去溶剂,制得β-酮酸酯(3),可不经纯化直接用于下一步。
实施例二 5-烷基-6-(取代苄基/环己甲基)- 2-硫基-3H-嘧啶-4-酮(4)的制备
在干燥的反应瓶中,将10 g(0.43 mol)金属钠分批加入300 mL无水乙醇中,待钠溶解冷却后,一次性加入24 g(0.315 mol)硫脲,然后滴加β-酮酸酯(3)的乙醇溶液20 mL,将混合物加热回流5—7个小时,TLC追踪至β-酮酸酯原料点消失后停止加热,冷却,减压蒸去溶剂,将残余物溶于300 mL水中,用浓盐酸调pH值为6左右,有大量白色沉淀产生,抽滤,用水洗涤滤饼,烘干得5-烷基-6-(取代苄基/环己甲基)- 2-硫基-3H-嘧啶-4-酮(4),可不经纯化直接用于下一步目标化合物的合成。
实施例三2-[(取代苯基) 羰基甲硫基]-6-取代苄基/环己甲基-5-烷基-3H-嘧啶-4-酮类化合物(5)的制备
将2 mmol的6-(取代苄基/环己甲基)-5-烷基-2-硫基-3H-嘧啶-4-酮(4)和2 mmol的K2CO3置于反应瓶中,加入无水N,N-二甲基甲酰胺(DMF)15 mL,于室温下搅拌30 min后,加入各α-溴代苯乙酮2.2 mmol,室温搅拌12—16小时,TLC追踪至原料点消失,停止反应,加入冰水100 mL,有白色沉淀生成,抽滤,用乙醇重结晶,部分需用柱层析纯化得纯品。
实施例四:5-烷基-2-[2-羟基-2-取代苯乙基硫]- 6-取代苄基/环己甲基-3H-嘧啶-4-酮(6)的合成
反应的一般操作:
将26 mmol 的5-烷基-2-[(取代苯基) 羰基甲硫基]-6-取代苄基/环己甲基-3H-嘧啶-4-酮(5)置于带有磁力搅拌的干燥三颈瓶中,加入20 mL的四氢呋喃和甲醇的混合溶液,于冰浴条件,在搅拌下分批加入NaBH4 (31.2 mmol),冰浴下继续搅拌反应3-4小时,TLC跟踪原料点消失,滴加少量水猝灭反应,减压除去溶剂,加入20 mL水稀释,再加入6 M的盐酸调pH = 6 ,用乙酸乙酯萃取溶液,无水Na2SO4干燥,减压浓缩得固体粗品,经柱层析纯化得5-烷基-2-[2-羟基-2-取代苯乙基硫]- 6-取代苄基/环己甲基-3H-嘧啶-4-酮的白色固体纯品。
从不同的5-烷基-2-[(取代苯基) 羰基甲硫基]-6-取代苄基/环己甲基-3H-嘧啶-4-酮出发,按上述方法操作,得目标化合物6a-m,其结构如表1所示,理化常数及光谱数据如下:
6-(4-氟苄基)- 2-[2-(4-氟苯基)-2-羟基乙基硫]-5-甲基- 3H-嘧啶-4-酮6a,白色固体,产率35%,熔点:194-195℃; 1 HNMR (DMSO-d 6 , 500 MHz) (ppm): 1.79(s,3H,CH 3),3.07(s, 2H, -CH 2-Ph), 3.63-3.64 (m, 2H, CH 2S), 4.28(s, OH), 4.59-4.61(m,1H,CH-Ph),6.68-6.75(m, 4H, Ph-H),6.92-7.02(m, 4H, Ph-H); MS(ESI): m/z 387.1[M+-1]。
2-[2-(4-氟苯基)-2-羟基乙基硫]- 6-(4-甲氧苄基)-5-甲基- 3H-嘧啶-4-酮6b,白色固体,产率35%,熔点: 139-140℃; 1 HNMR (DMSO-d 6 ,400 MHz) (ppm): 1.79(s,3H,CH 3),5.83(m, OH),3.36(s, 2H,-CH 2- ph),3.67-3.72 (m, 2H, CH 2S),3.77(s, 3H, OCH 3),4.73-4.75(m, 1H, CH-Ph),6.81-6.93 (m, 2H, Ph-H),7.13-7.36 (m, 6H, Ph-H);MS(ESI): m/z 399.1[M+-1].
2-(2-羟基-2-苯基乙基硫)-6-(4-甲氧苄基)-5-甲基-3H-嘧啶-4-酮6c,白色固体,产率45%,熔点: 129-130℃; 1 HNMR (DMSO-d 6 ,400 MHz) (ppm): 1.94(s, 3H, CH 3),3.13-3.16(m, OH), 3.38-3.52 (s, 2H, -CH 2- Ph),3.69(s, 3H, OCH 3),3.79(m, 2H, CH 2S),4.72-4.75(m, H, CH-Ph),6.81-6.85(m, 2H, Ph-H),7.15-7.18(m, 2H, Ph-H),7.24-7.26(m, H, Ph-H),7.27-7.29(m, 4H, Ph-H);MS(ESI): m/z 381.5 [M+-1].
2-[2-羟基-2-(4-甲氧基苯基)乙基硫]-6-(4-甲氧苄基)- 5-甲基-3H-嘧啶-4-酮6d,白色固体,产率42%,熔点: 138-139℃; 1 HNMR (DMSO-d 6 ,400 MHz) (ppm): 1.99(s,3H,CH 3),3.13-3.18(m, OH), 3.37 (m, 2H, -CH 2- Ph),3.69(s, 3H, OCH 3),3.74(s, 3H, OCH 3),3.78(d, J=6.9Hz, 2H,CH 2S), 4.66-4.69(m, 1H, CH-Ph),6.82-6.89(m, 4H, Ph-H),7.15-7.32(m, 4H, Ph-H), 12.58 (s, brs, NH);MS(ESI): m/z 411.6[M+-1].
2-[2-羟基-2-(4-甲氧基苯基)乙基硫]-6-(4-羟苄基)-5-甲基-3H-嘧啶-4-酮6e,白色固体,产率43%,熔点: 230-230.1℃; 1 HNMR (DMSO-d 6 ,500 MHz) (ppm):2.25(s,3H,CH 3),3.65(s,3H,OCH 3),3.70 (s, 2H, -CH 2-Ph) ,3.74-3.76(m, OH), 3.84-3.85(d, J=6.9Hz, 2H, CH 2S),5.39-5.42(m, 1H, CH-Ph),7.04-7.05(d, 2H, J=8.5, Ph-H),7.16-7.17 (m, 2H, Ph-H),7.39-7.41(d, 2H, J=8.3, Ph-H),7.68-7.70(d, 2H, J=8.5Hz, Ph-H),8.71(s, 1H, Ph-OH);MS (ESI): m/z 397.2[M+-1].
5-乙基-6-(4-氟苄基)-2-[2-(4-氟苯基)-2-羟基乙基硫]-3H-嘧啶-4-酮6f, 白色固体,产率35%,熔点: 131.2-131.5℃; 1 HNMR (DMSO-d 6 ,500 MHz) (ppm): 1.05-1.07(t, J=7.4Hz, 3H, CH2CH 3), 2.55-2.60(q, 2H, J=7.4Hz, CH 2CH3), 3.19-3.22 (bra, OH), 3.20(s, 2H, -CH 2- Ph),3.88-3.95(m, 2H, CH 2S),4.92-4.94(m, H, CH-Ph),6.97- 7.02 (m, 4H, Ph-H),7.19-7.26(m, 4H, Ph-H),10.65 (s, brs,1H, NH); MS(ESI): m/z 401.2[M+-1].
5-乙基-6-(4-氟苄基)- 2-(2-羟基-2-苯基乙基硫)- 3H-嘧啶-4-酮6g,白色固体,产率38%,熔点: 147.8-148.1℃; 1 HNMR (DMSO-d6,500 MHz) (ppm): 0.99-1.03(t, J=9.2Hz, 3H, CH2CH 3), 2.48-2.53(q, 2H, J=9.2Hz, CH 2CH3),3.16-3.22(s, 2H,-CH 2- Ph),3.61-3.62(bra, OH), 3.81-3.90(m, 2H, CH 2S) ,4.86-4.88(m, H, CH-Ph),6.91-6.95(m,2H,Ph-H),7.15-7.30(m, 7H, Ph-H),12.45 (s, brs,1H, NH);MS(ESI): m/z 383.3 [M+-1].
5-乙基-6-(4-氟苄基)-2-[2-羟基-2-(4-甲氧基苯基)乙基硫] - 3H-嘧啶-4-酮6h,白色固体,产率33%,熔点: 206.6-207℃; 1 HNMR (DMSO-d 6 ,500 MHz) (ppm): 1.01-1.04(t, 3H, J=7.4Hz, CH2CH 3), 2.50-2.52(q, 2H, J=7.4Hz, CH 2CH3),2.69(bra, OH),3.17-3.21(m, 2H, -CH 2- Ph),3.76(s, 3H, OCH 3),3.84-3.86(m, 2H, CH 2S) , 4.82-4.84(m, 1H, CH-Ph),6.81-6.95(m,4 H, Ph-H),7.14-7.25(m, 4H, Ph-H);MS(ESI): m/z 413.2[M+-1].
6-(环己基甲基) -2-[2-(4-氟苯基)-2-羟基乙基硫]- 5-甲基-3H-嘧啶-4-酮6i, 白色固体,产率48%,熔点: 194-195℃; 1 HNMR (DMSO-d 6 ,400 MHz) (ppm): 0.94-1.13(m,5H,cyclohexyl), 1.60-1.64(m,6H, cyclohexyl),1.70-1.75(bra, OH),1.86(s, 3H, CH 3), 2.37-2.39(d, 2H, J=6.4, -CH 2 cyclohexyl),3.46-3.50(m, 2H, CH 2S),4.80-4.83(dd, J 1 =4.0 Hz, J 2 =4.4Hz, H, CH-Ph),7.14-7.19(m, 2H, Ph-H),7.42-7.45(m, 2H, Ph-H) 12.25 (s, brs, NH);MS(ESI): m/z 375.0 [M+-1].
6-(环己基甲基)-2-(2-羟基-2-苯基乙基硫)-5-甲基-3H-嘧啶-4-酮6j, 白色固体,产率45%,熔点: 148-149℃; 1 HNMR (DMSO-d 6 ,400 MHz) (ppm): 0.95-1.19 (m, 5H, cyclohexyl), 1.53-1.79(m,6H, cyclohexyl),1.76-1.78(s, OH),1.87(s, 3H, CH 3),2.36-2.40 (d, 2H, J=2.4Hz, -CH 2cyclohexyl),3.51-3.54(m, 2H, CH 2S),4.78-4.81(m, H, CH-Ph), 7.25-7.42 (m,6H, Ph-H), 12.55 (s, brs,1H, NH);MS(ESI): m/z 357.3[M+-1].
6-(环己基甲基)- 2-[2-羟基-2-(4-甲氧基苯基)乙基硫]-5-甲基- 3H-嘧啶-4-酮6k,白色固体,产率48%,熔点: 203-204℃; 1 HNMR (DMSO-d 6 ,500 MHz) (ppm): 1.02-1.23(m, 5H, cyclohexyl), 1.64-1.81(m, 6H, cyclohexyl), 1.77-1.80(bra, OH), 2.01(s, 3H, CH 3), 2.48-2.50(d, 2H, J=7.0Hz, -CH 2cyclohexyl), 3.47-3.49(s, 2H, CH 2S), 3.80(s, 3H, OCH 3), 5.03-5.04(m, 1H, CH-Ph), 6.88-6.89(m, 2H, Ph-H), 7.25-7.34(m, 2H, Ph-H).; MS(ESI): m/z 373.3[M+-1].
6-(环己基甲基)- 5-乙基-2-[2-(4-氟苯基)-2-羟基乙基硫]-3H-嘧啶-4-酮6l, 白色固体,产率56%,熔点: 164-164.2℃; 1 HNMR (DMSO-d6,500 MHz) (ppm):0.95-0.98(t, 3H, J=7.3Hz, CH2CH 3),1.13 (m, 5H, cyclohexyl), 1.61-1.64(m, 6H, cyclohexyl), 1.78(bra, OH),2.33-2.38(q, J=7.2Hz, 2H, CH 2CH3),2.50-2.51(m, OH),3.14-3.17(m, 2H, -CH 2 cyclohexyl),3.48-3.50(m, 2H, CH 2S),4.81-4.83(m, H, CH-Ph),7.13-7.17(m, 2H, Ph-H),7.42-7.45(m, 2H, Ph-H), 12.15 (s, brs,1H, NH);MS(ESI): m/z 389.1 [M+-1].
6-(环己基甲基)-5-乙基-2-[2-羟基-2-(4-羟基苯基)乙基硫]-3H-嘧啶-4-酮6m,白色固体,产率46%,熔点: 164-164.2℃; 1 HNMR (CDCl3,500 MHz) (ppm): 0.93-0.96(t, 3H, J=7.35, CH2CH 3), 1.12(m, 5H, cyclohexyl),1.58-1.62(m, 6H, cyclohexyl),1.77(bra, OH),2.33-2.34(q, 2H, J=7.2Hz, CH 2CH3),3.07-3.11(m, 2H, -CH 2 cyclohexyl),3.38-3.42(m, 2H, CH 2S),4.67-4.69(m, 1H, CH-Ph),6.70-6.72(d, 2H, J=8.3Hz, Ph-H),7.17-7.18(m, 2H, J=8.3Hz, Ph-H);MS(ESI): m/z 387.2[M+-1].
实施例五:体外抗HCV活性实验
采用人肝癌细胞株Huh 7.5.1进行体外细胞水平抗HCV活性评价。方法描述如下:
MTT法检测药物细胞毒性:取对数生长期的Huh 7.5.1细胞,以9×103 cells/well细胞铺于96孔板,贴壁5小时后,加入2 μL DMSO梯度稀释药物,5倍稀释,5个稀释度,每个梯度设有三个重复孔,同时设置空白对照(只含培养基)、细胞对照、药物颜色对照、DMSO对照及抗HCV阳性药物利巴韦林对照,终体积200 μL/well。将培养板置于37℃、5%CO2培养箱进行培养。第三天于实验孔加入20 μL的5 mg/mL MTT溶液,37℃、5%CO2孵育4小时。弃去上清,加入150 μL/well的DMSO,振荡溶解10 分钟后,于酶标仪上测定OD490的值,并以Graphad Prism 5.0计算药物IC50 (IC50:半数抑制浓度,将细胞生长抑制50%所需的浓度)的值。计算公式:细胞生长抑制率(%) = (1– 试验孔OD值 / 对照孔OD值)×100% 。
复制抑制试验:取对数生长期的Huh 7.5.1细胞,以9×103 cells/well细胞铺于96孔板,贴壁5小时后,加入2 μLDMSO梯度稀释药物,5倍稀释,5个稀释度,每个梯度设有三个重复孔,同时加入病毒,设细胞对照、病毒对照、抗HCV阳性对照(IFNα-1b及利巴韦林)、DMSO对照,终体积200 μL/well。将培养板置于37℃、5%CO2培养箱进行培养,3天后收集上清3000 rpm/min离心10 min,取澄清上清进行RNA载量检测。以Graphad Prism 5.0计算HCV复制抑制率及EC50(EC50:半数效应浓度,引起受试对象50%个体产生一种特定效应的药物剂量)。计算公式:HCV复制抑制率(%)=(1–试验孔HCV RNA载量/对照孔HCV RNA载量)×100%
抗HCV药效评价:治疗指数(Therapeutic index, TI)为药物对细胞的半数抑制浓度IC50和对病毒的半数效应浓度的比值,代表药物的安全性,此数值越大越安全。
以抗HCV临床治疗药物Ribavirin和IFNα-1b(IU/ml)作为阳性对照。按上述方法对合成的13个化合物(6a-m)进行了药物细胞毒性和抗HCV病毒活性筛选,具体测试数据(IC50、EC50及TI值)参见表2,从表中可见,所测的13个化合物中有10个化合物治疗指数高于Ribavirin,其中活性最好的三个化合物6g、6l、6m治疗指数比Ribavirin高6-12倍,可作为抗HCV的先导物加以利用。
表2. 化合物6a-m的IC50、EC50及TI值
编号 | R 1 | R 2 | R 3 | IC 50 (μM) | EC 50 (μM) | TI |
6a | CH3 | 4’-F | 113.27 | 10.48 | 10.80 | |
6b | CH3 | 4’-F | 126.05 | 10.83 | 11.63 | |
6c | CH3 | H | 74.78 | 7.50 | 9.97 | |
6d | CH3 | 4’-OCH3 | 75.83 | 6.44 | 11.77 | |
6e | CH3 | 4’-OCH3 | 122.11 | 5.08 | 24.05 | |
6f | C2H5 | 4’-F | 52.50 | 2.29 | 22.9 | |
6g | C2H5 | H | 92.41 | 1.65 | 55.67 | |
6h | C2H5 | 4’-OCH3 | 186.45 | 13.62 | 13.70 | |
6i | CH3 | 4’-F | 103.38 | 16.23 | 6.37 | |
6j | CH3 | H | 30.88 | 4.42 | 6.98 | |
6k | CH3 | 4’-OCH3 | 54.10 | 10.99 | 4.92 | |
6l | C2H5 | 4’-F | 39.95 | 0.34 | 116.35 | |
6m | C2H5 | 4’-OH | 29.57 | 0.26 | 113.73 | |
Ribavirin | 93.65 | 10.01 | 9.35 | |||
IFNα-1b(IU/ml) | 1.452μg/ml | - |
Claims (3)
2.如权利要求1所述2-(2-羟基-2-取代苯乙基硫基)-3H-嘧啶-4-酮类化合物的制备方法,其特征在于:以5-烷基-2-[(取代苯基)羰基甲硫基]-6-取代苄基/环己甲基-3H-嘧啶-4-酮类化合物为原料,在四氢呋喃和甲醇混合溶液中,冰浴条件下用NaBH4还原制备目标分子。其中,5-烷基-2-[(取代苯基)羰基甲硫基]-6-取代苄基/环己甲基-3H-嘧啶-4-酮类化合物与NaBH4的摩尔比为1∶1.2,反应溶液为四氢呋喃和甲醇的混合溶液,反应温度为冰浴条件,反应时间为3~4小时。
3.如权利要求1所述的2-(2-羟基-2-取代苯乙基硫基)-3H-嘧啶-4-酮类化合物的用途,其特征在于作为抗丙型肝炎药物候选物,或者是作为不同剂型的抗HCV药物组合物的活性成分。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201110358811.5A CN102399197B (zh) | 2011-11-14 | 2011-11-14 | 2-(2-羟基-2-取代苯乙基硫基)-3h-嘧啶-4-酮类化合物及其合成方法与用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201110358811.5A CN102399197B (zh) | 2011-11-14 | 2011-11-14 | 2-(2-羟基-2-取代苯乙基硫基)-3h-嘧啶-4-酮类化合物及其合成方法与用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102399197A true CN102399197A (zh) | 2012-04-04 |
CN102399197B CN102399197B (zh) | 2014-04-16 |
Family
ID=45881900
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201110358811.5A Expired - Fee Related CN102399197B (zh) | 2011-11-14 | 2011-11-14 | 2-(2-羟基-2-取代苯乙基硫基)-3h-嘧啶-4-酮类化合物及其合成方法与用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102399197B (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105384696A (zh) * | 2015-10-29 | 2016-03-09 | 云南大学 | 多取代1,6-二氢嘧啶类化合物、其合成方法及用途 |
CN106866549A (zh) * | 2017-04-26 | 2017-06-20 | 云南大学 | 一种S‑DACOs类NNRTIs及其制备方法和用途 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101037415A (zh) * | 2007-01-09 | 2007-09-19 | 云南大学 | S-dabo类化合物、其合成方法和用途 |
-
2011
- 2011-11-14 CN CN201110358811.5A patent/CN102399197B/zh not_active Expired - Fee Related
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101037415A (zh) * | 2007-01-09 | 2007-09-19 | 云南大学 | S-dabo类化合物、其合成方法和用途 |
Non-Patent Citations (3)
Title |
---|
YAN-PING HE ET AL.: "Synthesis and biological evaluation of novel dihydro-aryl/alkylsulfanyl-cyclohexylmethyl-oxopyrimidines (S-DACOs)as high active anti-HIV agents", 《BIOORGANIC & MEDICINAL CHEMISTRY LETTERS》 * |
ZHI-KUN RAO ET AL.: "Synthesis and anti-HIV-1 activity of S-dihydro(alkyloxy)benzyloxypyrimidine derivatives", 《MONATSH CHEM》 * |
马英: "《药物化学》", 31 July 2007, 河南科学技术出版社 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105384696A (zh) * | 2015-10-29 | 2016-03-09 | 云南大学 | 多取代1,6-二氢嘧啶类化合物、其合成方法及用途 |
CN106866549A (zh) * | 2017-04-26 | 2017-06-20 | 云南大学 | 一种S‑DACOs类NNRTIs及其制备方法和用途 |
Also Published As
Publication number | Publication date |
---|---|
CN102399197B (zh) | 2014-04-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102206172B (zh) | 一组取代双芳基化合物及其制备方法和抗病毒应用 | |
CN104395330B (zh) | 尿嘧啶基螺氧杂环丁烷核苷 | |
AU751201B2 (en) | Methods for treating or preventing viral infections and associated diseases | |
CN103987712B (zh) | 2’,3’-二脱氧-2’-α-氟-2’-β-C-甲基核苷和其前药 | |
CN105669565B (zh) | 异长叶烷基嘧啶类化合物及其制备方法与应用 | |
CN103360398B (zh) | 一种***并嘧啶类hiv-1逆转录酶抑制剂及其制备方法与应用 | |
CN104230905A (zh) | 一类含苯并二噁烷骨架的二氢吡唑磺胺衍生物的合成及在抗癌药物中的应用 | |
CN103333168B (zh) | 一种酰胺类化合物及其制备方法与应用 | |
CN102399197B (zh) | 2-(2-羟基-2-取代苯乙基硫基)-3h-嘧啶-4-酮类化合物及其合成方法与用途 | |
CN109422710A (zh) | 一种索非布韦氟内酯中间体的制备方法 | |
CN109265504A (zh) | 4-氨基酸取代嘧啶核苷化合物及其药物用途 | |
CN104945388A (zh) | 4-(3-(3-(4-氯香豆素)-酰腙)-5-苯基-吡唑)苯磺酰胺类衍生物的制备方法及在抗癌药物中的应用 | |
CN102173997A (zh) | 抗肝癌、胃癌和子***的大黄素衍生物及其制备方法 | |
CN102649788B (zh) | β-L-2’-脱氧-胸腺嘧啶核苷衍生物及其制备方法和用途 | |
US8173610B2 (en) | Derivatives of epirubicin, their medicinal application and pharmaceuticaly acceptable forms of drugs | |
CN105384696A (zh) | 多取代1,6-二氢嘧啶类化合物、其合成方法及用途 | |
CN102675205A (zh) | 一种吡唑肟醚类化合物及其制备与在抗癌治疗中的应用 | |
CN104098526B (zh) | 酰胺苯基-1,3,4-噁二唑类化合物及其制备方法和应用 | |
KR101233082B1 (ko) | 신규한 이미다졸피라진 유도체 화합물 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 항바이러스 치료용 약학적 조성물 | |
CN102532037B (zh) | 新型嘧啶衍生物及其制备方法和应用 | |
CN106674318B (zh) | 一种ns5b聚合酶抑制剂 | |
CN106674320B (zh) | 一种hcv的治疗药物 | |
CN106928250B (zh) | 2-噁二唑-3-氨基噻吩并[2,3-b]吡啶衍生物及其制备方法和用途 | |
CN106674319B (zh) | 一种治疗丙肝的化合物 | |
CN107721930A (zh) | 取代的1‑(2‑氟苯基)‑3‑(3‑丙基己基)脲类化合物、药物组合物及用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20140416 Termination date: 20171114 |